Compare · ABT vs ELVN
ABT vs ELVN
Side-by-side comparison of Abbott Laboratories (ABT) and Enliven Therapeutics Inc. (ELVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ELVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 54.1x ELVN ($3.24B).
- Over the past year, ABT is down 18.6% and ELVN is up 134.3% - ELVN leads by 152.9 points.
- ABT has been more active in the news (12 items in the past 4 weeks vs 8 for ELVN).
- ABT has more recent analyst coverage (25 ratings vs 9 for ELVN).
- Company
- Abbott Laboratories
- Enliven Therapeutics Inc.
- Price
- $100.68+1.91%
- $53.16+4.63%
- Market cap
- $175.37B
- $3.24B
- 1M return
- +11.09%
- +25.08%
- 1Y return
- -18.60%
- +134.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 9
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest ELVN
- Director Kunkel Lori Anne sold $504,903 worth of shares (10,000 units at $50.49) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 41,884 units (SEC Form 4)
- Large owner Orbimed Advisors Llc sold $39,014,046 worth of shares (860,123 units at $45.36) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Enliven Therapeutics Inc.
- SEC Form 144 filed by Enliven Therapeutics Inc.
- SEC Form 144 filed by Enliven Therapeutics Inc.
- SEC Form 144 filed by Enliven Therapeutics Inc.
- CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 6,018 shares at a strike of $2.48 and sold $263,577 worth of shares (6,018 units at $43.80) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF MEDICAL OFFICER Collins Helen Louise sold $219,017 worth of shares (5,000 units at $43.80) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)
- Large owner Orbimed Advisors Llc sold $12,668,988 worth of shares (281,408 units at $45.02) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Enliven Therapeutics Inc.